Patients affected by recurrent seizures frequently present increased homocysteine plasma levels in consequence of treatment with antiepileptic drugs. Homocysteine is proconvulsant and can affect the response to antiepileptic drugs. In addition, high homocysteine plasma levels represent a risk factor for cardiovascular and neurodegenerative diseases. To better define the role of increased homocysteine in epilepsy, we analyzed the effects of homocysteine pretreatment in the pilocarpine model of status epilepticus (SE), which is used to mimic temporal lobe epilepsy (TLE) in rodents. Precisely, we investigated whether a moderate hyperhomocysteinemia, unable to cause seizures, could sensitize rats to pilocarpine and cooperate in inducing brain lesions. We found that a subthreshold dose of pilocarpine (200 mg/kg) is sufficient to induce SE in the majority (approximately 90%) of rats pretreated with homocysteine for 2 weeks, whereas only 40% of saline-treated controls developed SE following the same pilocarpine dose. Furthermore, homocysteine pretreatment led to a significant increase in neuronal cell loss evaluated by counting toluidine blue-stained or Fluoro-Jade-positive cells in hippocampal and parahippocampal regions. Pilocarpine augmented amyloid beta expression in both animal groups. However, pretreatment with homocysteine favored the intraneuronal fibrillar conformation of amyloid beta, thus promoting neurodegeneration. These findings indicate that increased homocysteine levels enhance seizure activity and neurodegeneration in pilocarpine-treated rats and suggest that similar detrimental effects may occur in patients affected by TLE.

Homocysteine potentiates seizures and cell loss induced by pilocarpine treatment / Baldelli, Enrica; Leo, Giuseppina; Andreoli, Nicola; K., Fuxe; Biagini, Giuseppe; Agnati, Luigi Francesco. - In: NEUROMOLECULAR MEDICINE. - ISSN 1535-1084. - STAMPA. - 12:(2010), pp. 248-259. [10.1007/s12017-009-8110-1]

Homocysteine potentiates seizures and cell loss induced by pilocarpine treatment

BALDELLI, Enrica;LEO, Giuseppina;ANDREOLI, NICOLA;BIAGINI, Giuseppe;AGNATI, Luigi Francesco
2010-01-01

Abstract

Patients affected by recurrent seizures frequently present increased homocysteine plasma levels in consequence of treatment with antiepileptic drugs. Homocysteine is proconvulsant and can affect the response to antiepileptic drugs. In addition, high homocysteine plasma levels represent a risk factor for cardiovascular and neurodegenerative diseases. To better define the role of increased homocysteine in epilepsy, we analyzed the effects of homocysteine pretreatment in the pilocarpine model of status epilepticus (SE), which is used to mimic temporal lobe epilepsy (TLE) in rodents. Precisely, we investigated whether a moderate hyperhomocysteinemia, unable to cause seizures, could sensitize rats to pilocarpine and cooperate in inducing brain lesions. We found that a subthreshold dose of pilocarpine (200 mg/kg) is sufficient to induce SE in the majority (approximately 90%) of rats pretreated with homocysteine for 2 weeks, whereas only 40% of saline-treated controls developed SE following the same pilocarpine dose. Furthermore, homocysteine pretreatment led to a significant increase in neuronal cell loss evaluated by counting toluidine blue-stained or Fluoro-Jade-positive cells in hippocampal and parahippocampal regions. Pilocarpine augmented amyloid beta expression in both animal groups. However, pretreatment with homocysteine favored the intraneuronal fibrillar conformation of amyloid beta, thus promoting neurodegeneration. These findings indicate that increased homocysteine levels enhance seizure activity and neurodegeneration in pilocarpine-treated rats and suggest that similar detrimental effects may occur in patients affected by TLE.
12
248
259
Homocysteine potentiates seizures and cell loss induced by pilocarpine treatment / Baldelli, Enrica; Leo, Giuseppina; Andreoli, Nicola; K., Fuxe; Biagini, Giuseppe; Agnati, Luigi Francesco. - In: NEUROMOLECULAR MEDICINE. - ISSN 1535-1084. - STAMPA. - 12:(2010), pp. 248-259. [10.1007/s12017-009-8110-1]
Baldelli, Enrica; Leo, Giuseppina; Andreoli, Nicola; K., Fuxe; Biagini, Giuseppe; Agnati, Luigi Francesco
File in questo prodotto:
File Dimensione Formato  
art%3A10.1007%2Fs12017-009-8110-1.pdf

non disponibili

Tipologia: Versione pubblicata dall'editore
Dimensione 861.96 kB
Formato Adobe PDF
861.96 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/628778
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 27
  • ???jsp.display-item.citation.isi??? 28
social impact